NCT04162353 - BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Multiple Myeloma in RelapseRefractory Multiple MyelomaPlasmacytoid; Lymphoma

Interventions

BIOLOGICAL

BCMA-CD19 cCAR T cells

BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy

Trial Locations (2)

Unknown

RECRUITING

Peking University Shenzhen Hospital, China, Shenzhen

RECRUITING

Chengdu Military General Hospital, Chengdu